Skip to main content

Advertisement

Volume 10 Supplement 1

de Senectute: Age and Health Forum

Tumours of the prostate

Article metrics

  • 685 Accesses

Background

In the United States, Prostate cancer is the most common tumour in men, with an expected 192.280 new cases and 27.360 deaths estimated in 2009 [1]. About 81% of patients with prostate cancer are over 65 years of age. Prostate cancer is a biologically heterogeneous neoplasm in which, especially in the elderly, some forms remain silent and with risk of disease-treatment. Moreover, this population may not receive optimal therapies for their disease, if decisions are based only on their chronological age. Health status, more than age, is a major factor affecting individual life expectancy. Comorbidity is the key predictor of health status, and should weigh more on the treatment decision than age alone. Other important parameters to consider in the elderly are the degree of dependence in activities of daily living, the nutritional status and the presence or not of a geriatric syndrome. The androgen-deprivation therapy (ADT) has become an integral piece of the armamentarium for treating prostate cancer in neoadjuvant, adjuvant and palliative therapy [2]. The impact on health-related quality of life (HRQOL) following ADT induction has gained significant clinical attention. Several series documented an association between ADT and declining HRQOL [3]. Treatment of hormone refractory metastatic prostate cancer with Docetaxel 75 mg/m2 every 3 weeks (3W) in combination with daily prednisone has been shown to prolong survival and to have the same efficacy in healthy elderly as in younger patients [4].

Conclusions

Geriatric assessment in elderly patients with prostate cancer is crucial. Each treatment has to be adapted to health status.

References

  1. 1.

    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics, 2009. Ca Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.

  2. 2.

    Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD: Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006, 18 (4): CD006019-

  3. 3.

    Dacal K, Sereika SM, Greenspan SL: Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc. 2006, 54: 85-90. 10.1111/j.1532-5415.2005.00567.x.

  4. 4.

    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel and prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004, 351: 1502-1512. 10.1056/NEJMoa040720.

Download references

Author information

Correspondence to F Grillone.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Grillone, F. Tumours of the prostate. BMC Geriatr 10, L37 (2010) doi:10.1186/1471-2318-10-S1-L37

Download citation

Keywords

  • Prostate Cancer
  • Docetaxel
  • Prednisone
  • Heterogeneous Neoplasm
  • Geriatric Assessment